FONDAZIONE TELETHON ETS
- Country
- 🇮🇹Italy
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://telethon.it
Clinical Trials
12
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Methodology Study of Retroviral Insertion Site Analysis in Strimvelis Gene Therapy
- Conditions
- Severe Combined Immunodeficiency Due to ADA Deficiency
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Fondazione Telethon
- Target Recruit Count
- 15
- Registration Number
- NCT04959890
- Locations
- 🇮🇹
Ospedale San Raffaele, Milan, Italy
A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome
- Conditions
- Wiskott-Aldrich Syndrome
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Fondazione Telethon
- Target Recruit Count
- 10
- Registration Number
- NCT03837483
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Inc, Atlanta, Georgia, United States
🇮🇹Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET), Milan, Italy
Natural History Study in Subjects With Usher Syndrome
- Conditions
- Usher Syndrome, Type 1B
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Fondazione Telethon
- Target Recruit Count
- 56
- Registration Number
- NCT03814499
- Locations
- 🇮🇹
Eye Clinic of the University of Campania Luigi Vanvitelli, Naples, Italy
🇳🇱Stichting Oogziekenhuis Rotterdam, Rotterdam, Netherlands
🇪🇸Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Madrid, Spain
Use of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency.
- Conditions
- Pyruvate Dehydrogenase Complex Deficiency
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Fondazione Telethon
- Target Recruit Count
- 1
- Registration Number
- NCT03734263
- Locations
- 🇮🇹
Federico II University, Napoli, Italy
Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)
- Conditions
- Immunologic Deficiency Syndromes
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Fondazione Telethon
- Target Recruit Count
- 50
- Registration Number
- NCT03478670
- Locations
- 🇮🇹
Ospedale San Raffaele, Milano, Lombardia, Italy
- Prev
- 1
- 2
- Next
News
Can-Fite Advances Piclidenoson to Phase II Trial for Rare Lowe Syndrome with No Current Treatments
Can-Fite BioPharma has completed the design of a Phase II clinical trial for Piclidenoson in Lowe Syndrome, a rare genetic disease affecting approximately 1 in 500,000 people with no approved treatments.